Note: The below is an edited version of a press release by UniQure. The original release can be read in it’s entirety here.
On June 11, 2016, uniQure N.V. announced that additional data from its Phase I/II clinical trial of AMT-060 in hemophilia B patients were presented at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark. Study investigator Dr. Frank Leebeek, Professor of Hematology at Erasmus University Medical Center in Rotterdam, gave an oral presentation of a comprehensive overview of results from five patients that received a single administration of uniQure’s novel gene therapy, AMT-060. Data from low-dose cohort showed durable and therapeutically relevant factor IX (FIX) expression, with a median FIX activity for the five patients in the trial at 5.4.
Read the press release from uniQure in it’s entirety here.
